Morepen Laboratories Ltd
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
- Market Cap ₹ 2,509 Cr.
- Current Price ₹ 49.0
- High / Low ₹ 56.4 / 25.1
- Stock P/E 30.9
- Book Value ₹ 16.0
- Dividend Yield 0.00 %
- ROCE 9.32 %
- ROE 6.84 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 65.0 days to 111 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
270 | 303 | 336 | 370 | 452 | 548 | 561 | 717 | 792 | 1,112 | 1,449 | 1,339 | 1,482 | |
252 | 274 | 290 | 324 | 388 | 487 | 501 | 652 | 728 | 1,000 | 1,320 | 1,262 | 1,361 | |
Operating Profit | 18 | 29 | 46 | 47 | 64 | 60 | 60 | 65 | 64 | 112 | 129 | 77 | 121 |
OPM % | 7% | 10% | 14% | 13% | 14% | 11% | 11% | 9% | 8% | 10% | 9% | 6% | 8% |
13 | 6 | 4 | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 12 | |
Interest | 8 | 12 | 10 | 9 | 10 | 7 | 4 | 2 | 2 | 2 | -7 | 2 | 3 |
Depreciation | 47 | 46 | 46 | 39 | 35 | 34 | 33 | 38 | 34 | 28 | 21 | 18 | 20 |
Profit before tax | -24 | -23 | -6 | 1 | 16 | 23 | 26 | 29 | 37 | 94 | 126 | 63 | 109 |
Tax % | 0% | 0% | 0% | 19% | -1% | 0% | 0% | 0% | 14% | 0% | 20% | 27% | |
-24 | -23 | -6 | 1 | 16 | 23 | 26 | 29 | 32 | 94 | 101 | 46 | 81 | |
EPS in Rs | -0.54 | -0.50 | -0.14 | 0.01 | 0.35 | 0.52 | 0.58 | 0.64 | 0.72 | 2.10 | 2.11 | 0.90 | 1.59 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 19% |
3 Years: | 19% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 12% |
3 Years: | 13% |
TTM: | 62% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 23% |
3 Years: | 4% |
1 Year: | 81% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 15% |
3 Years: | 16% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 |
Reserves | 143 | 121 | 115 | 103 | 119 | 134 | 161 | 188 | 217 | 311 | 476 | 678 | 714 |
Preference Capital | 120 | 120 | 120 | 120 | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
121 | 111 | 89 | 81 | 67 | 168 | 134 | 139 | 142 | 17 | 19 | 25 | 27 | |
228 | 220 | 214 | 226 | 259 | 155 | 206 | 203 | 212 | 429 | 443 | 300 | 321 | |
Total Liabilities | 583 | 542 | 508 | 500 | 535 | 548 | 591 | 619 | 662 | 848 | 1,033 | 1,106 | 1,164 |
374 | 331 | 289 | 244 | 216 | 191 | 182 | 153 | 135 | 144 | 156 | 171 | 194 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 20 |
Investments | 122 | 122 | 118 | 118 | 118 | 118 | 118 | 118 | 119 | 119 | 118 | 118 | 125 |
87 | 89 | 100 | 138 | 201 | 239 | 291 | 349 | 408 | 583 | 745 | 800 | 825 | |
Total Assets | 583 | 542 | 508 | 500 | 535 | 548 | 591 | 619 | 662 | 848 | 1,033 | 1,106 | 1,164 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
27 | 33 | 33 | 51 | 50 | 49 | 61 | 15 | 11 | 49 | -69 | -102 | |
-3 | -3 | -1 | -30 | -27 | -15 | -24 | -10 | -12 | -69 | -23 | -36 | |
-22 | -30 | -29 | -20 | -28 | -31 | -38 | -0 | 5 | 47 | 66 | 144 | |
Net Cash Flow | 2 | 1 | 3 | 1 | -5 | 3 | -1 | 4 | 3 | 28 | -25 | 6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45 | 44 | 44 | 48 | 65 | 55 | 72 | 62 | 56 | 51 | 56 | 70 |
Inventory Days | 78 | 70 | 60 | 56 | 53 | 68 | 79 | 71 | 93 | 84 | 95 | 85 |
Days Payable | 131 | 105 | 122 | 124 | 140 | 126 | 176 | 123 | 111 | 95 | 80 | 86 |
Cash Conversion Cycle | -8 | 9 | -18 | -21 | -22 | -3 | -25 | 10 | 38 | 40 | 71 | 69 |
Working Capital Days | -35 | -30 | -16 | -16 | -6 | -91 | -66 | -31 | -4 | 22 | 62 | 111 |
ROCE % | -6% | -3% | 0% | 2% | 8% | 8% | 8% | 8% | 9% | 22% | 23% | 9% |
Documents
Announcements
- Compliance Certificate (RTA & Company) For The Financial Year Ended March 31, 2024 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 16 Apr
- Corporate Presentation 15 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 10 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
Leadership in Anti-Asthmatic drug
The company is world leader in Loratadine (140 MT) and has achieved the leadership position of being one of the largest suppliers of anti-asthmatic drug, Montelukast Sodium (85 MT). It is a prominent player in commercial production of drugs Atorvastatin calcium (120 MT), Rosuvastatin calcium of anti-hypercholesterolemic series, Fexofenadine Hydrochloride of antihistamine series, Olmesartan of anti-hypertensive series & their intermediates. [1] [2]